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The SR protein splicing factor SRSF1 is a potent
proto-oncogene that is frequently upregulated in
cancer. Here, we show that SRSF1 is a direct target
of the transcription factor oncoprotein MYC. These
two oncogenes are significantly coexpressed in
lung carcinomas, and MYC knockdown downregu-
lates SRSF1 expression in lung-cancer cell lines.
MYC directly activates transcription of SRSF1
through two noncanonical E-boxes in its promoter.
The resulting increase in SRSF1 protein is sufficient
to modulate alternative splicing of a subset of
transcripts. In particular, MYC induction leads to
SRSF1-mediated alternative splicing of the signaling
kinase MKNK2 and the transcription factor TEAD1.
SRSF1 knockdown reduces MYC’s oncogenic
activity, decreasing proliferation and anchorage-
independent growth. These results suggest amecha-
nism for SRSF1 upregulation in tumors with elevated
MYC and identify SRSF1 as a critical MYC target that
contributes to its oncogenic potential by enabling
MYC to regulate the expression of specific protein
isoforms through alternative splicing.INTRODUCTION
SRSF1 (formerly SF2/ASF) is a prototypical member of the SR
protein family, a conserved class of splicing regulators. Besides
its central roles in constitutive and alternative splicing (Ge and
Manley, 1990; Krainer et al., 1990; Mayeda and Krainer, 1992),
SRSF1 regulates other aspects of RNA metabolism, including
mRNA stability (Sun et al., 2011; Lemaire et al., 2002), nuclear
export (Huang et al., 2003), nonsense-mediated mRNA decay
(Zhang and Krainer, 2004), translation (Sanford et al., 2004),
and miRNA processing (Wu et al., 2010). The SRSF1 gene is
essential, and depletion of the protein triggers genomic insta-
bility, cell-cycle arrest, and apoptosis (Xu et al., 2005; Li et al.,
2005), whereas its overexpression drives transformation of
immortal rodent fibroblasts (Karni et al., 2007). SRSF1 negatively
autoregulates its expression through various posttranscriptional
and translational mechanisms (Sun et al., 2010; Wu et al., 2010),
yet despite this stringent homeostatic control, it is frequently up-110 Cell Reports 1, 110–117, February 23, 2012 ª2012 The Authorsregulated in many different cancers (Ezponda et al., 2010; Karni
et al., 2007; Thorsen et al., 2011). SRSF1 resides on Chromo-
some 17q23, a locus that is amplified in some tumors (Sinclair
et al., 2003), accounting for some instances of SRSF1 overex-
pression (Karni et al., 2007).
Altered transcriptional regulation might also cause SRSF1
overexpression in tumors. MYC (alias c-Myc) is a potent onco-
genic transcription factor that is frequently overexpressed or
hyperactive inmany cancers (Adhikary and Eilers, 2005). Consis-
tent with a possible role of MYC in regulating SRSF1, the SRSF1
promoter region directly or indirectly binds MYC, according to
a ChIP-on-Chip analysis of CpG island arrays (Mao et al.,
2003); in addition, expression microarray analyses reported
SRSF1 among >100 genes upregulated in response to MYC in
multiple cell lines (Coller et al., 2000; Schlosser et al., 2005).RESULTS AND DISCUSSION
Considering that SRSF1 is markedly overexpressed in lung
cancer (Ezponda et al., 2010; Karni et al., 2007), we analyzed
public microarray data from a panel of 132 lung tumors, to deter-
mine whether MYC overexpression correlates with elevated
SRSF1 levels in this context. Indeed, we found a strong positive
correlation between MYC and SRSF1 expression at the RNA
level (Figure 1A). Among eight other known or putative MYC-
regulated splicing factors we analyzed (David et al., 2010;
Li et al., 2003; Rauch et al., 2011; Zeller et al., 2003), only
HNRNPH1 and PTBP1 expression correlated significantly with
MYC expression in these lung-tumor samples (Table S1 avail-
able online). We extended this analysis to a panel of normal
and tumor-derived lung cell lines, and also found a significant
correlation at the protein level between MYC and SRSF1 (Fig-
ure 1B), with most cancer cell lines overexpressing both
proteins, relative to IMR90 primary lung fibroblasts. In contrast,
MYC expression did not correlate in these cells with that of other
SR proteins, such as SRSF9 (Figure 1B) and SRSF6 (data not
shown). siRNA-mediated knockdown of MYC in two of these
cell lines, the large cell lung cancer cell line NCI.H460 and the
bronchoalveolar adenocarcinoma cell line NCI.H1666, resulted
in significant decreases in SRSF1 expression, both at the tran-
script and protein level, indicating that SRSF1 expression is
under MYC control (Figures 1C and 1D). However, another
bronchoalveolar adenocarcinoma cell line, A549, did not show
this effect, indicating additional context-dependent levels of
control (Figure S1); this may be due to threshold effects, as
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Figure 1. SRSF1 Expression Correlates with MYC
Levels in Human Lung Tumors and Cell Lines
(A) SRSF1 expression profile from microarray analysis
of 132 lung tumors (expO). The data were normalized
to Z-score and divided into two categories: tumors ex-
pressing high or low MYC levels. The dot plot shows
the distribution and the median (horizontal line). Mann-
Whitney test ***p < 0.0001.
(B) Immunoblotting of MYC and SRSF1 in lung-cancer cell
lines and lung primary fibroblasts, showing significant
correlation between the expression of the two oncopro-
teins (r = 0.75, one-tailed t test *p = 0.05).
(C) RT-PCR and (D) Immunoblotting of MYC and SRSF1 in
NCI.H460 and NCI.H1666 cells transfected with control
siRNA (luciferase) or one of two siRNAs against MYC.
See also Figure S1.A549 cells have relatively low levels of both MYC and SRSF1
(Figure 1B). The imperfect correlation between SRSF1 and
MYCexpression in the lung cancer cell lines (Figure 1B) indicates
that though MYC is an important regulator of SRSF1 expression,
SRSF1 overexpression in cancer is not solely attributable to
MYC expression; additional factors likely affect its expression
at the transcriptional, posttranscriptional, translational, or post-
translational levels.
To assess more directly whether SRSF1 expression is regu-
lated by MYC, we used an inducible MYC-Estrogen Receptor
(ER) system (Eilers et al., 1989; Littlewood et al., 1995). We
generated IMR90 cells stably expressing the MYC protein fused
to a modified ER ligand-binding domain, which binds the
synthetic estrogen analog 4-hydroxytamoxifen (4-OHT). The
ER.MYC protein is held in the cytoplasm through association
with the HSP-90 protein. Upon binding 4-OHT, ER.MYC translo-
cates into the nucleus, where it regulates the expression of target
genes. 4-OHT treatment of IMR90-ER.MYC cells led to signifi-
cant accumulation of SRSF1 mRNA (Figure 2A) and SRSF1
protein (Figure 2B). As a control for ER.MYC induction, we veri-
fied the upregulation of a known MYC target gene, NCL (Fig-
ure S2A). Moreover, IMR90 cells transduced with empty vector
did not induce SRSF1 upon 4-OHT treatment (Figure S2B). A
MYC deletion mutant lacking amino acids 106–143, which
comprise MYC Box II (MBII) in the transcription-activation
domain (TAD) (Oster et al., 2003), failed to induce SRSF1 expres-
sion (Figures 2A and 2B), indicating that MYC requires an intact
TAD to upregulate SRSF1 expression. We also observed
increased SRSF1 levels upon MYC induction in two immortal
cell lines: MCF-10A mammary epithelial cells and Rat1a fibro-
blasts (Figure S2C). Two additional SR protein genes, SRSF5
and SRSF11, showed no change in expression upon MYC
induction, though both were predicted as MYC target genes byCell Reports 1, 110a genome-wide ChIP-on-Chip analysis (Li
et al., 2003; Figure S2D). In addition to showing
the specificity of the effect of MYC on SRSF1,
these results emphasize the need for validation
to determine the true MYC targets among those
predicted by genome-wide analyses.
We next analyzed the splicing of two previ-
ously reported SRSF1 target genes, MKNK2and TEAD1 (Karni et al., 2007). MKNK2 encodes the eIF4E-
kinase MNK2 and expresses two isoforms by alternative splicing
of 30 exons 13A and 13B, whereas TEAD1 encodes the transcrip-
tional enhancer factor protein TEF-1 and expresses two isoforms
by alternative splicing of exon 5. IMR90 cells overexpressing
SRSF1 predominantly expressed the +13B isoform of MKNK2
and the +5 isoform of TEAD1, as expected (Karni et al., 2007;
(Figure 2C, lanes 1 and 2). Another splicing factor, hnRNPA1,
which is also positively regulated by MYC (Biamonti et al.,
1993; David et al., 2010) and frequently antagonizes SRSF1
(Mayeda and Krainer, 1992), did not alter MKNK2 or TEAD1
splicing (Figure 2C, lane 3). Induction of IMR90-ER.MYC cells
with 4-OHT promoted a significant switch in MKNK2 splicing
from the +13A to the +13B isoform and promoted inclusion of
exon 5 in the TEAD1 transcript, consistent with the increase
in SRSF1 (Figure 2C, lanes 4 and 5). Furthermore, induction of
ER.MYC in cells transfected with siRNA against SRSF1 did not
trigger a change inMKNK2 or TEAD1 splicing (Figure 2C, lane 6),
indicating that MYC alters MKNK2 and TEAD1 splicing through
upregulation of SRSF1 expression. We also observed that
both SRSF1 overexpression and MYC induction led to a sig-
nificant increase in the overall MKNK2 transcript level
(Figure S2E), suggesting that both factors directly or indirectly
regulate MKNK2 expression at the level of transcription or
mRNA stability. We also measured alternative splicing of a
third SRSF1 target gene, BIN1, which encodes the tumor
suppressor and pro-apoptotic protein BIN1. SRSF1 overexpres-
sion promotes inclusion of the 12A exon in the BIN1 transcript
(Karni et al., 2007). However, we did not observe changes in
alternative splicing of BIN1 in response to MYC induction
(Figure S2F), perhaps due to other splicing factors also being
modulated by MYC and counteracting the SRSF1-mediated
inclusion of exon 12A.–117, February 23, 2012 ª2012 The Authors 111
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Figure 2. MYC Regulates SRSF1 Expression and Alternative Splicing of SRSF1 Target Genes
(A and B) (A) RT-PCR and (B) Immunoblotting of SRSF1 from IMR90-ER.MYC or IMR90-ER.MYCDMBII cells induced with 4-OHT. Error bars, SD; n = 3; t test
**p < 0.01.
(C) RT-PCR ofMKNK2 and TEAD1mRNA isoforms in IMR90-ER.MYC cells induced with 4-OHT, with or without SRSF1 knockdown. IMR90 cells overexpressing
SRSF1 or hnRNPA1 are shown as controls. Error bars, SD; n = 3, *p < 0.05.
See also Figure S2.Because MYC was predicted to bind the SRSF1 promoter
by ChIP-on-Chip analysis of CpG islands (Mao et al., 2003),
we investigated whether SRSF1 is a direct transcriptional target
of MYC. Treatment of IMR90-ER.MYC cells with the protein-
synthesis inhibitor cycloheximide prior to 4-OHT induction of
ER.MYC did not abrogate the upregulation of SRSF1 mRNA
(Figure 3A), indicating that de novo protein synthesis is not
required for MYC to activate SRSF1 expression. Moreover,
analysis of the human SRSF1 promoter sequence revealed112 Cell Reports 1, 110–117, February 23, 2012 ª2012 The Authorsthree putative noncanonical MYC binding sites (E-boxes). We
therefore used ChIP to assess binding of MYC to the SRSF1
promoter locus in the lung-carcinoma cell line NCI.H460,
which downregulates SRSF1 expression in response to MYC
knockdown (Figures 1C and 1D). Our ChIP analysis revealed
significant enrichment of MYC at the SRSF1 proximal promoter
region comprising two E-boxes mapping at 412 and 39,
relative to the transcription start site (Figure 3B). We also
detected MYC enrichment at a third E-box at position +146,
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Figure 3. MYC Binds to and Activates the Human SRSF1 Promoter
(A) RT-PCR of IMR90-ER.MYC cells treated with 4-OHT, with or without cycloheximide. Error bars, SD; n = 3; **p < 0.01.
(B) MYC chromatin immunoprecipitation analysis at the SRSF1 promoter locus in the lung carcinoma NCI-H460 cell line. Diagram of the SRSF1 gene indicating
the E-boxes and amplicons (A-E) used for ChIP assays. The results are expressed as DNA enrichment in fragmented chromatin immunoprecipitated with anti-
MYC antibody (relative to anti-rabbit IgG immunoprecipitation) and normalized to the amplicon E signal, asmeasured by quantitative PCR. The horizontal gray line
represents no change in MYC-specific enrichment. Error bars, SD; n = 3; t test *p < 0.05; n.s., not significant.
(C) Diagram of the wild-type SRSF1 promoter, comprising three noncanonical E-boxes, and the E-Box mutants generated for reporter assays. Mutant E-boxes
and residues are indicated in red. (D) Luciferase assay of reporter constructs in (C) cotransfected withMYC cDNA or vector control into NIH 3T3 cells. Luciferase
activity was normalized to cotransfected GFP, and the relative activity is plotted. Error bars, SD; n = 3; t test **p < 0.01; n.s., not significant.relative to the transcription start site, but this was not signifi-
cant and likely corresponds to chromatin fragments that over-
lap the E-box at 39 (Figure 3B). MYC binding to the SRSF1
proximal promoter region is also evident in genome-wide
data from HeLa and K562 cells obtained by the ENCODE
genome-wide ChIP sequencing project (UCSC genome
browser, assembly NCBI36/hg18, Yale/UC Davis/Harvard
study). The same study also reported the binding of MYC’s
obligate heterodimerization partner MAX (Amati and Land,
1994) to the SRSF1 proximal promoter region, suggesting
MYC activity at the locus.CTo determine whether these are functional MYC binding sites,
we amplified a 1,500 bp genomic fragment of the SRSF1
promoter, comprising these putative E-boxes (from 1,200
to +300 relative to the transcription-start site [TSS]), inserted it
upstream of a luciferase reporter gene, and assayed for its
MYC responsiveness in transfected NIH 3T3 cells. We also
generated constructs with mutations in the three E-boxes, either
individually or together, to an inactive CACTCA sequence
(Figure 3C). MYC overexpression resulted in 3-fold induction
of luciferase activity for the wild-type construct (Figure 3D),
relative to the vector control. The double, but not the individual,ell Reports 1, 110–117, February 23, 2012 ª2012 The Authors 113
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Figure 4. SRSF1 Knockdown Impairs Anchorage-Independent Growth of MYC-Transformed Cells
(A) Immunoblotting of MYC and SRSF1 in the Rat1a-pBabe-Luc control cell line, Rat1a-MYC, and Rat1a-MYC cells transduced with one of two shRNAs
against SRSF1.
(B) Growth curves of the four cell lines from (A). Error bars, SD; n = 3.
(C) Anchorage-independent growth of cell lines from (A) in soft-agar colony-formation assays. Error bars, SD; n = 3; t test *p < 0.05.mutations of E-boxes 1 and 2 abrogated this MYC-induced
activation, suggesting functional redundancy between the two
elements (Figure 3D). Mutation of the third putative noncanonical
E-box (E-box 3), downstream of the TSS, either alone or in
combination with the other E-boxes, did not abrogate, or further
reduce, luciferase activity, indicating that this site is nonfunc-
tional (Figure 3D). We conclude that SRSF1 is a direct transcrip-
tional target of MYC, with two functional noncanonical E-boxes
in its promoter.
Both MYC and SRSF1 are strong oncogenes that control
cell proliferation, cell-cycle progression, and apoptosis. We
therefore asked whether SRSF1 induction is required for MYC-
induced transformation. We generated MYC-overexpressing
Rat1a fibroblasts transduced with either a control luciferase
shRNA or two different shRNAs against SRSF1. SRSF1 knock-
down was carefully modulated by optimizing the retroviral114 Cell Reports 1, 110–117, February 23, 2012 ª2012 The AuthorsMOI so as to cancel out the MYC-induced increase in SRSF1
protein, but without completely depleting it from the cells (Fig-
ure 4A). As expected, Rat1a-MYC cells showed elevated
SRSF1 expression and increased proliferation, compared to
Rat1a-pBabe-Luc control cells (Figure 4B). SRSF1 knockdown
resulted in a significant decrease in the proliferation rate of
the MYC-overexpressing cells, though it remained significantly
higher than the control. In accordance with this result, DNA-
content analysis by flow cytometry revealed a higher percentage
of the MYC-overexpressing cells in the S-G2-M phase, com-
pared to the vector control (Figure S3). SRSF1 knockdown
significantly decreased the proportion of dividing cells, with
more cells accumulating in the G0-G1 phases. Moreover,
SRSF1 knockdown did not promote cell death, ruling out
apoptosis as a cause of the observed decrease in growth rate
(Figure S3). Rat1a-MYC-SRSF1sh cells showed significantly
decreased anchorage-independent growth, compared to
Rat1a-MYC cells (Figure 4C). We conclude that SRSF1 is a
critical MYC target gene, required for MYC’s full activity in
tumorigenesis.
Recently, MYC was shown to regulate the expression of other
splicing factors—hnRNPA1, hnRNPA2, PTB1, and hnRNPH—
and through them to regulate alternative splicing of pyruvate
kinase M and oncogenic A-Raf kinase pre-mRNAs (David
et al., 2010; Rauch et al., 2011). In the present study, we show
MYC-mediated positive regulation of the oncogenic splicing
factor SRSF1. MYC activates transcription from the SRSF1
promoter, and the resulting increase in SRSF1 leads to altered
splicing of some but not all of its target genes. Furthermore,
we found SRSF1 to be a critical MYC target, necessary for
MYC’s oncogenic activity. We have also found that SRSF1 and
MYC cooperate in transforming mammary epithelial cells, and
their expression correlates in human breast tumors (Anczuko´w
et al., 2012). The SRSF1 target genes that do undergo a splicing
change upon MYC induction are therefore likely to be important
mediators of MYC activity. Furthermore, considering the role
of SRSF1 in multiple processes other than splicing, such as
translation and mTOR signaling, there are likely several addi-
tional downstream effectors of SRSF1 that contribute to MYC
function. The overall picture that emerges from these studies is
that, in addition to regulating transcription of its target genes,
MYC also indirectly regulates the expression of protein isoforms
through regulation of alternative splicing of a subset of tran-
scripts, and these changes contribute to MYC’s biological
functions.
EXPERIMENTAL PROCEDURES
Plasmids
T7-tagged SRSF1 and HNRNPA1 cDNAs cloned in the pBABE-Puro
retroviral vector were described previously (Karni et al., 2007). pBABE-
Puro-ER.MYC (Littlewood et al., 1995) was used to generate the pBabe-
Puro-ER.MYCDMBII construct by Quick-change site-directed mutagenesis
(Stratagene). The Transcriptional Regulatory Element Database (TRED)
(Zhao et al., 2005) was used to obtain the SRSF1 promoter sequence
(Promoter ID 18315). The SRSF1 promoter from 1,200 to +300 (relative
to the TSS) was amplified from human genomic DNA (Promega) and
cloned into the pGL3 vector (Promega). MYC-binding sites in the wild-
type SRSF1 promoter were mutated by Quick-change site-directed
mutagenesis.
Cell Culture and Stable Cell Line Generation
IMR90, NIH 3T3, and Rat1a cells were grown in DMEM medium (Invitrogen)
supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin, and strepto-
mycin. NCI-H524, NCI-H460, NCI-H1299, NCI-H1568, and NCI-H1975 cells
were grown in RPMI 1640 medium (Invitrogen) supplemented with 10% (v/v)
FBS, penicillin, and streptomycin. A549 cells were grown in F12K medium
(Invitrogen) supplemented with 10% (v/v) FBS. NCI-H1666 cells were grown
in DMEM/F12medium (Invitrogen) supplemented with 5% (v/v) FBS, penicillin,
and streptomycin. MCF10A cells were grown in DMEM/F12 medium, supple-
mented with 5% (v/v) horse serum, 20 ng/ml EGF, 100 mg/ml hydrocortisone,
10 ng/ml cholera toxin, penicillin, and streptomycin. To generate stable pools,
IMR-90 and Rat1a cells were infected with pBABE-Puro or pBABE-hygro
retroviral vectors expressing ER.MYC or MYC cDNAs, respectively, followed
by selection with puromycin (2 mg/ml) or hygromycin (200 mg/ml) for 72 hr.
For MYC induction studies, ER.MYC-expressing cells were grown to conflu-
ence and treated with 2 mM 4-OHT for 8 hr for RT-PCR, and 48 hr for immuno-
blotting and splicing analysis.CRNA Interference
For inhibition of MYC or SRSF1 expression, cells were seeded (2 3 105 cells
per well) in 6-well plates in antibiotic-free medium. After 24 hr, cells were
transfected with 200 pmol short interfering RNA against MYC (Cell Signaling,
Catalog No. 6553) or SRSF1 (target sequence 50-ACGAUUGCCGCAU
CUACGU-30) using Lipofectamine RNAiMAX (Invitrogen). After a further
48 hr, cells were lysed, and protein and RNA were extracted as described
below. For stable knockdown of SRSF1, Rat1a cells were separately
transduced with each of two SRSF1 shRNAs cloned in the retroviral vector
LMP9, and selected with 2 mg/ml puromycin for 4 days.
Immunoblotting
Cells were lysed in RIPA buffer and protein was quantitated using a Bradford
Protein Assay kit (Bio-Rad). Total protein (25 mg) from each lysate was
separated by SDS-PAGE and transferred onto a nitrocellulose membrane
(Whatman), followed by blocking with 5% (w/v) dry milk in Tris-buffered saline
with 0.05% (v/v) Tween-20, probing with the indicated antibodies, and quan-
titation using an Odyssey infrared-imaging system (LI-COR Biosciences).
Primary antibodies used were: MYC (Cell Signaling rAb, 1:500); SRSF1 (mAb
AK96 culture supernatant (Hanamura et al., 1998), 1:500); SRSF9 (mAb culture
supernatant, 1:50); b-actin (Sigma mAb, 1:10,000), and b-tubulin (Genscript
rAb, 1:10,000). Secondary antibodies were IRdye 800 or 680 anti-rabbit or
anti-mouse (LI-COR Biosciences, 1:10,000).
RT-PCR Analysis
Cells were lysed with Trizol reagent (Invitrogen) and total RNA was extracted.
Following DNAase I digestion (Promega), 2 mg of total RNA was reverse-
transcribed with Improm-II reverse transcriptase (Promega). Radioactive
PCR (25 cycles) with [a-32P]-dCTP was used to amplify endogenous
transcripts. The products were run on a 5% native polyacrylamide gel, visual-
ized by autoradiography, and quantitated on a FUJIFILM FLA-5100 phos-
phorimager (Fuji Medical Systems) using Multi Gauge software Version 2.3
(Fujifilm). The PCR primers used were as follows:
hSRSF1F: 50-ATGTCGGGAGGTGGTGTGATTC-30
hSRSF1R: 50-TGTTCCACGGCCGCTTCGAG-30
rSRSF1F: 50-CGCGACATCGACCTGAAGAAC-30
rSRSF1R: 50-CCACGACACCAGTGCCATCTCG-30
HNRNPA1F: 50-AAAGACCAGGTGCCCACTTA-30
HNRNPA1R: 50-AATCTTATCCACGGAGTCATGG-30
MYCF: 50-GGTACAAGCTGGAGGTGGAG-30
MYCR: 50-AATCTTATCCACGGAGTCATGG-30
NCLF: 50-TTTCTTTCCTTTGGCTGGTG-30
NCLR: 50-ATGGCAAGAATGCCAAGAAG-30
MKNK2Ex11F: 50-CCAAGTCCTGCAGCACCCCTG-30
MKNK2Ex13aR: 50-GATGGGAGGGTCAGGCGTGGTC-30
MKNK2Ex13bR: 50-GAGGAGGAAGTGACTGTCCCAC-30
TEAD1Ex3, 4F: 50-AGACGAAGGCAAAATGTATGG-30
TEAD1Ex9, 8R: 50-CGTAGGCTCAAACCCTGGAAT-30
BIN1Ex11F: 50-CCTCCAGATGGCTCCCCTGC-30
BIN1Ex15R: 50-CCCGGGGGCAGGTCCAAGCG-30
b-actinF: 50-GTGCCCATTTATGAGGGCTA-30
b-actinR: 50-CTGGCAGCTCGTAGCTCTTT-30
Chromatin Immunoprecipitation
ChIP assays were performed as described (Steger et al., 2008). Crosslinking
was performed with sequential 15 mM EGS (Pierce) and 1% (v/v) formalde-
hyde treatment. Antibodies used for immunoprecipitation were rabbit anti-
myc (Cell Signaling, 9402) and rabbit IgG (Cell Signaling). Immunoprecipitated
DNA was analyzed by quantitative PCR using SYBR green (ABI) on an ABI
7900HT instrument. PCR primers were as follows:
Amplicon A:
F: 50-CCCAGCCTGATTTGAATTTT-30
R: 50-GAAAATACCGGTCCTCTCAGG-30
Amplicon B:
F: 50-GGATTAGACGCACCCTACGA-30ell Reports 1, 110–117, February 23, 2012 ª2012 The Authors 115
R: 50-CGATTTCTCCAGGAATGAGG-30
Amplicon C:
F: 50-ACGTAGCCCTCGCAGCAC-30
R: 50-GGACTCGAGAACAGGCCTTC-30
Amplicon D:
F: 50-CTTTTCGTCACCGCCATGT-30
R: 50-GTCCTCGAACTCAACGAAGG-30
Amplicon E:
F: 50-GGATTGATGTGAAGGGACGA-30
R: 50-TGGAATCCAGAGTCCAAAAT-30
Luciferase Reporter Assay
MYC expression vector (500 ng), 100 ng of pGL3-Luciferase reporter
comprising nucleotides 1,200 to +300 of the SRSF1 promoter—with or
without E-box mutations—and 100 ng of pEGFP vector were cotransfected
into NIH 3T3 cells using Fugene 6 (Roche). Thirty-six hours after transfection,
the cells were lysed, and luciferase activity was measured using a Dual
Luciferase Reporter Assay kit (Promega). RNA was extracted from the
remaining cell lysate, and the GFP level was measured by radioactive RT-PCR
and used as a transfection control to normalize luciferase activity.
Growth Curves and Proliferation Assay
Rat1a cells transduced with pBABE-hygro, pBABE-MYC, LMP-Puro, LMP-
SRSF1sh1, or LMP-SRSF1sh2 were seeded at 1 3 105 cells per 60 mm
dish. At the indicated times, triplicate plates of cells were trypsinized, stained
with Trypan blue, and unstained cells were counted using a hemocytometer.
Anchorage-Independent Growth
Rat1a cells from each transductant pool were plated (20,000 cells per well)
in triplicate in 0.35% (w/v) agar in DMEM supplemented with 10% (v/v) FBS
on a layer of 0.7% (w/v) agar. Cells were incubated at 37C and 5% (v/v)
CO2 for 14 days. Colonies were stained with 0.005% (w/v) Crystal Violet,
and whole-well images were taken using the Odyssey Imaging System. The
images were analyzed using Image-J software, and the average number of
colonies per well for each transductant pool was determined.
Microarray Analysis
The GEO GSE2109 data set from the Expression Project for Oncology
(http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc = GSE2109)
was used to obtain expression profile data from 132 clinically annotated
human lung tumors. Each sample was standardized by calculating Z-scores
based on the sample average and SD across the entire set of genes. Expres-
sion profiles of SRSF1 and MYC were extracted for all the samples. A contin-
gency table was built showing the number of samples with high expression of
both SRSF1 and MYC, only SRSF1, only MYC, or neither (Z-score >1.29,
corresponding to a p value of 0.1). A Mann-Whitney test was used to compare
SRSF1 expression in lung tumors containing high versus low MYC levels
(above and below the median).
Statistical Analysis
All histograms were plotted using mean ± SD. Data points were compared
using unpaired two-tailed Student’s t tests, and p values are indicated in
the figure legends. Pearson correlation was used to evaluate the associa-
tion between MYC and SRSF1 expression detected by quantitative
immunoblotting.
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